Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing  by Dhaenens, C.M. et al.
Biochimica et Biophysica Acta 1812 (2011) 732–742
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isMis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by
overexpression of CELF2 but not by MBNL1 silencing
C.M. Dhaenens a,b,1, H. Tran a,b,1, M.-L. Frandemiche a,b, C. Carpentier a,b, S. Schraen-Maschke a,b,1,
A. Sistiaga c,d,g,1, M. Goicoechea c,d,g, S. Eddarkaoui a,b, E. Van Brussels a,b, H. Obriot a,b, A. Labudeck e,
M.H. Gevaert e, F. Fernandez-Gomez a,b, N. Charlet-Berguerand f, V. Deramecourt e, C.A. Maurage a,b,e,
L. Buée a,b, A. Lopez de Munain c,d,g,1, B. Sablonnière a,b, M.L. Caillet-Boudin a,b, N. Sergeant a,b,⁎,1
a Inserm, U837-1, Alzheimer & Tauopathies, place de Verdun, F-59045 Lille, France
b Univ Lille Nord de France, UDSL, Faculty of Medicine, Institute of Predictive Medicine and Therapeutic Research, Jean-Pierre Aubert Research Centre, place de Verdun, F-59045 Lille, France
c Donostia Hospital, Experimental Unit, Paseo Dr. Begiristain s/n, 20014 San Sebastian, Spain
d Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) C/ Valderrebollo, 528031 Madrid, Spain
e CHULille, Neuropathological Department, Regional University Hospital Centre, F-59037 Lille, France
f Inserm, AVENIR Group, IGBMC, 1 Rue Laurent FRIES, 67404 Illkrich, France
g Donostia Hospital, Neurological Unit, Po Dr Begiristain s/n, 20014 San Sebastian, Spain⁎ Corresponding author at: Inserm U837-1, Alzheimer
de France, USDL, IMPRT, Batiment Biserte, 1, place de Ve
Lille, France.
E-mail address: nicolas.sergeant@inserm.fr (N. Serge
1 Equal contribution to the work.
0925-4439/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbadis.2011.03.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 June 2010
Received in revised form 16 March 2011
Accepted 17 March 2011
Available online 23 March 2011
Keywords:
Myotonic dystrophy
Triplet expansion disease
Microtubule-associated protein Tau
Splicing
CELF splicing factor family
MBNL1Tau is the proteinaceous component of intraneuronal aggregates common to neurodegenerative diseases called
Tauopathies, including myotonic dystrophy type 1. In myotonic dystrophy type 1, the presence of microtubule-
associated protein Tau aggregates is associated with a mis-splicing of Tau. A toxic gain-of-function at the
ribonucleic acid level is a major etiological factor responsible for the mis-splicing of several transcripts in
myotonic dystrophy type 1. These are probably the consequence of a loss ofmuscleblind-like 1 (MBNL1) function
or gain of CUGBP1 and ETR3-like factor 1 (CELF1) splicing function. Whether these two dysfunctions occur
together or separately andwhether all mis-splicing events inmyotonic dystrophy type 1 brain result fromone or
both of these dysfunctions remains unknown.Here,we analyzed the splicing of Tau exons 2 and 10 in the brain of
myotonic dystrophy type 1 patients. Two myotonic dystrophy type 1 patients showed a mis-splicing of exon 10
whereas exon 2-inclusion was reduced in all myotonic dystrophy type 1 patients. In order to determine the
potential factors responsible for exon 10 mis-splicing, we studied the effect of the splicing factors muscleblind-
like1 (MBNL1), CUGBP1 and ETR3-like factor 1 (CELF1), CUGBP1 and ETR3-like factor 2 (CELF2), and CUGBP1 and
ETR3-like factor 4 (CELF4) or a dominant-negative CUGBP1 and ETR-3 like factor (CELF) factor on Tau exon 10
splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by CUGBP1 and
ETR3-like factor 2 (CELF2) whereas it is insensitive to the loss-of-function of muscleblind-like 1 (MBNL1),
CUGBP1and ETR3-like factor 1 (CELF1) gain-of-function, or a dominant-negative of CUGBP1 and ETR-3 like factor
(CELF) factor. Moreover, we observed an increased expression of CUGBP1 and ETR3-like factor 2 (CELF2) only in
the brain of myotonic dystrophy type 1 patients with a mis-splicing of exon 10. Taken together, our results
indicate the occurrence of a mis-splicing event in myotonic dystrophy type 1 that is induced neither by a loss of
muscleblind-like 1 (MBNL1) function nor by a gain of CUGBP1 and ETR3-like factor 1 (CELF1) function but is
rather associated to CUGBP1 and ETR3-like factor 2 (CELF2) gain-of-function.& Tauopathies, Univ Lille Nord
rdun, rue Polonowski, F-59045
ant).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Myotonic dystrophy type 1 (Steinert's disease) is an inherited
neuromuscular disease affecting multiple organs, including skeletal
and smooth muscle (myotonia), the heart (arrhythmias, conductiondefects), the endocrine system (hyperinsulinemia), and the eyes
(cataracts) [1]. The involvement of the central nervous system in DM1
was reported long ago [2,3], but systematic studies to analyze the brain
structures and cognitive functions involved have only recently been
initiated. The available clinical data suggest that patients experience
focused executive and visuoconstructive difﬁculties [4–7] and frontal
cognitive impairment including attentional ability worsening with
aging [8,9]. In addition, impairments in facial emotion recognition
have been associated with the adult form of DM1 [5]. These clinical
ﬁndings suggest the involvement of the cerebral cortex as well as
subcortical areas, such as the amygdala. In line with these
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beta peptide and Tau protein concentrations in the cerebrospinal ﬂuid
were shown to be signiﬁcantly reduced and increased, respectively, in
DM1 when compared to aged-matched control patients [10]. Struc-
tural neuroimaging in DM1 patients reveals the presence of brain
atrophy and white matter lesions [11–13].
At the neuropathological level, neuroﬁbrillary tangles (NFTs) are
found in the limbic system of DM1 patients, including the hippocampus
and isocortical areas such as the temporal and frontal cortices [14–16].
NFTs are intraneuronal aggregates made of hyper- and abnormally
phosphorylated isoforms ofmicrotubule-associated Tau (for review, see
reference 17). Tau proteins belong to the family of microtubule-
associated proteins and are encoded by a single MAPT gene located on
chromosome 17. The alternative splicing of Tau exons 2, 3, and 10 gives
rise to 6 adult human brain isoforms that are principally expressed in
neurons and localized preferentially in the axons. The alternative
splicing of Tau is developmentally regulated, tissue speciﬁc, and
deregulated in several Tauopathies [18]. In frontotemporal dementia,
MAPT gene mutations modify the splicing of Tau, leading to the
development of NFTs in adulthood. In DM1, we reported a modiﬁed
splicing pattern for Tau, essentially characterized by the reduced
inclusion of exons 2 and 3 [15,19]. A reduction in the inclusion of Tau
exon 10has also been reported in several brains fromDM1patients [20]
as well as in a transgenic animal model of DM1 [21]. However, the
molecular mechanism underlying the mis-splicing of exon 10 in DM1
and its functional consequences remain unknown. This is of importance
since the Tau exon10encodes for a fourthmicrotubule-binding domain.
Thus, Tau proteins with four microtubule-binding domains (4R) bind
more avidly and further stabilize microtubules than those with three
binding domains (3R). The increased expression of 3R Tau isoforms in
DM1 may modify the axonal transport and plasticity since Tau is
suggested to regulate the motor protein transport along microtubules
[22]. Moreover, a growing body of evidences suggests that Tau proteins
may also localize to spines of dendrites and regulate glutamatergic
transmission [23,24]. The splicing of N-methyl D-aspartate receptor
subunit one is altered in DM1 brains [19,20], which, together with the
mis-splicing of Tau, may also deregulate the glutamatergic synaptic
transmission. Thus, the reduced Tau protein isoforms expressed in DM1
brains and the development of NFT may contribute to the cognitive
impairments in DM1.
A toxic gain-of-function at the RNA level is the main pathophys-
iological hypothesis to explain the development of the disease. DM1 is
a genetically inherited disease characterized by a dynamic and
unstable trinucleotide repeat expansion in the 3′ UTR of the DMPK
gene [25]. DMPK transcripts bearing long CUG repeats are retained in
the nucleus and accumulate to form ribonuclear protein inclusions
called foci. This nuclear retention of mutated transcripts of DMPK is
responsible for DMPK haploinsufﬁciency. In addition, the sequestra-
tion inside foci of proteins such as members of the MBNL family of
splicing factors results in a partial loss-of-function of these splicing
factors [26,27]. Moreover, a gain-of-function of CUG-binding protein
and Elav-type RNA binding protein 3 (ETR3)-like factor 1 (CUG-
binding protein 1 (CUGBP1)/CELF1) in skeletal or heart muscle,
through its stabilization and phosphorylation by PKC, is also
instrumental to DM1 pathophysiology [28–30]. CELF1 and embryonic
lethal abnormal vision-like RNA-binding protein-3 (ETR3/CELF2) like
factors (CELF) belong to a family of RNA-binding proteins that
includes 6 members. While both CELF1 and CELF2 are ubiquitously
expressed, the latter is highly expressed in the brain and heart of
rodents [31,32]. The four other members, CELF3, 4, 5, and 6, are
enriched in the rodent brain. However, less is known about their
expression in the human brain and their potential implication in DM1.
Dysfunctions of MBNL1 and CELF1 together are responsible for the
modiﬁed splicing of several transcripts in DM1 muscle. However,
whether the two dysfunctions occur concomitantly or separately and
whether CELF family members other than CELF1 are involved in DM1brain remain to be determined. We previously suggested that a loss of
MBNL1 or a gain of CELF2 function could repress Tau exon 2-inclusion
as observed in human disease [19,33]. In the present study, we
extended our analysis to additional DM1 patients, and observed that,
in addition to the presence of NFTs in all DM1 patients, certain
patients displayed amis-splicing of exon 10 in addition to that of exon
2. We therefore investigated the factors potentially responsible for
this difference between patients as well as the mechanism involved in
the deregulation of Tau exon 10 splicing.
2. Results
2.1. Clinical and genetic presentation
In the present study, we ﬁrst analyzed the presence of DMPK CTG-
expansions, the brain distribution of NFTs, and Tau protein expression
in the brain tissue of two new DM1 patients (DM1a and DM1e) in
order to determine whether their phenotype was comparable to that
of the DM1 patients previously described [15]. Using small pool PCR
with 0.5 ng of DNA, we have observed CTG-expansion in 5 brain
regions in DM1a (Fig. 1A, left panel) and 6 regions in DM1e (Fig. 1A,
right panel). The smaller expanded allele of patient DM1a, visible in
the hippocampus and frontal and entorhinal cortices, was of 150 CTG
(Fig. 1A, left panel) and likely corresponds to the progenitor mutant
allele. The largest allele of patient DM1e, seen in the hippocampus,
contained 2900 CTG repeats, but several alleles with more than 1500
CTG repeats were observed in the other brain regions (Fig. 1A, right
panel). However, the number of expanded alleles detected is well
below that expected relative to the quantity of input DNA. The
number of expanded alleles and CTG repeat lengths were comparable
to those observed in the DM1 patients studied previously [15].
However, these data suggest that a high proportion of brain cells may
contain alleles too large to be efﬁciently ampliﬁed by PCR, resulting in
a probable underestimation of the true level of diversity within each
sample.
2.2. Brain distribution of NFTs and Tau isoform expression
In order to analyze Tau pathology and its topographic distribution
in the brain of DM1a and DM1e, the presence or absence of NFTs was
established in several brain regions, including the entorhinal, the
hippocampus, the amygdala, the basal and dorsolateral frontal, the
parietal and the occipital cortices, using immunohistochemistry
(Fig. 1B). NFTs composed of hyperphosphorylated Tau could be seen
using phospho-speciﬁc AT8, AD2, AT100, and S199P antibodies and a
pan TauCter antibody. Similar staining was observed in the amygdala
and hippocampus of patient DM1e (not shown). The immunohisto-
chemical observations were correlated with Western blotting studies
of Tau pathology. Using the phospho-speciﬁc Tau antibody AD2, we
observed the typical pathological Tau quartet of 60, 64, 69, and 74 kDa
in the sample fromanAlzheimer's disease (AD) patient (Fig. 1C, lanes 1
and 2). Tau proteins were not detected using the AD2 antibody in
control brain tissue (Fig. 1C and S1A, lanes 3 and 2, respectively).
Pathological Tau proteinswere detected and consisted of 2 bands of 60
and 64 kDa in the hippocampus (Fig. 1C, lane 5) and temporal
amygdala (Fig. 1C, lane 6) and a single band of 60 kDa in the entorhinal
cortex (Fig. 1C, lane 4) of DM1a, the insula, and temporal pole of DM1e
(Fig. S1A, lanes 3–6). We next used an antibody to the N-terminus of
Tau (TauNter) to analyze the overall expression of Tau protein
isoforms. Full-length Tau isoforms in the adult brain were resolved
as four bands in the control case (Fig 1C, lane 3; Fig. S1A, lane 2, dots).
The bands under the full-length isoforms correspond to catabolic
products. In all brain regions studied in both DM1a and DM1e, 2 main
bands were detected at 55 and 60 kDa, whereas the 64 kDa Tau band
was faintly labeled, and the upper bands were not detected (Fig. 1C
and Fig. S1A). In order to determine the Tau isoforms expressed inDM1
Fig. 1. CTG expansion mosaicism, neuroﬁbrillary degeneration, and Tau protein expression in DM1 brain tissue. A) CTG repeat lengths were determined from the genomic DNA of
cortical (frontal (Fr), temporal (Tp), amygdala (Tp am), insula (Ins), hippocampus (Hip), entorhinal (Ent), and occipital (Occ)) brain tissues of DM1a and DM1e using long PCR
followed by Southern blotting for expanded alleles. Results are shown for 0.5 ng of input DNA. Lane 1 (DM1a panel) corresponds to expanded control DNA (1300 CTG repeats) from a
congenital form of DM1. DNA molecular weight markers are indicated on the right. Dots indicate the longest expanded alleles for each brain region analyzed. B) Top: location of
epitopes recognized by the antibodies used with respect to the longest brain Tau isoform (441 aa isoform). Bottom: neuroﬁbrillary tangles (NFTs) in the amygdala of DM1a. NFTs
composed of abnormal and hyperphosphorylated Tau are stained by AT8, AD2, TauCter, AT100, and S199P antibodies. C) Spatial distribution of hyperphosphorylated Tau (PHF-Tau)
in DM1a brain. Using the phospho-speciﬁc Tau antibody AD2, hyperphosphorylated Tau isoforms (PHF-Tau) were detected only in brain regions with NFTs. Seven cortical brain
regions of DM1a (lanes 4 to 10: entorhinal (Ent), hippocampus (Hip), temporal amygdala (Tp am), basal frontal (Fr bas), dorsolateral frontal (Fr D-lat), parietal (Par), and occipital
(Occ)) were analyzed byWestern blotting using a Tau N-terminal antibody to detect all isoforms and compared to the frontal cortex of an Alzheimer's disease patient (lane 1 and 2)
and to the same region of a control individual (lane 3). In the control brain, Tau isoforms were detected as 4 bands between 50 and 67 kDa (black dots). Note that the bands under the
60 kDa Tau band detected with antibody TauNter correspond to amino-terminal catabolic products of Tau protein isoforms. The vertical bar indicates the position of the pathological
Tau protein quartet in lanes 1 and 2.
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case, 3 bands (55, 60, 64 kDa) corresponding to full-length Tau
isoformswere detected using an antibody to Tau isoforms lacking exon10 (Fig. S1B, panel Exon 10−). In contrast, the exon 10-speciﬁc
antibody stained strongly the 60 kDa band and, to a lesser extent, the
bands at 55 and 64 kDa (Fig. S1B, panel Exon 10+, lane Ctrl). The exon
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extent, the 64 kDa band. In both DM1a and DM1e, there was a strong
reduction of Tau isoforms stained with antibodies speciﬁc to exons 10
and 2 (Fig. S1B, panels Exon 10+ and Exon 2+), suggesting an
alteration in Tau protein isoform expression. We next determined the
composition of the Tau isoforms found in NFTs by immunohistochem-
istry, using Tau antibodies speciﬁc to exons 2 and 10 (Fig. S1C). As a
positive control, NFTs in an AD brain were stained with the AD2
phospho-Tau antibody as well as with Tau exon-speciﬁc antibodies
(Fig. S1C). In sharp contrast, in serial sections of the amygdala of
patient DM1a, no NFTs or neuropil threads were detected with exon-
speciﬁc Tau antibodies (Fig. S1C). This result suggests that no other
isoforms than those lacking exons 2 and 10 are found in NFTs of DM1
brains.
2.3. Tau splicing modiﬁcation in DM1 patients
Immunohistochemical and Western blot analyses indicate a mod-
iﬁed expression of Tau protein isoforms in the brain of patients DM1a
and DM1e, including the loss of Tau isoforms containing the sequence
encoded by exon 10. We therefore analyzed Tau isoform expression at
the mRNA level in ﬁve brain regions in comparison with previously
studied DM1 patients (Fig. 2 and Fig. S2). With regard to Tau exon 2/3
splicing, in the control brain, exon 2 was included in 53%±1% of Tau
transcripts (Fig. 2A, histogram). In the brain of DM1a and DM1e, this
proportion signiﬁcantlydropped to35%±3%(p=0.0079) and31%±2%
(pb0.0001), respectively, demonstrating a preferential skipping of exonFig. 2. Tau splicing in controls and DM1 patients. A) Exclusion of Tau exon 2 in the brain of DM
allowed the simultaneous ampliﬁcationofTau isoformswithexons2and3 (2+3+),with exon2
the hippocampus (Hip), temporal (Tp), parietal (Par), entorhinal (Ent), and frontal (Fr) cortica
loading standard. Right panel: histogram showing the percentage of transcripts containing exon
three individual RT–PCR experiments resulting from the study of four brain regions of two co
splicing inDM1 brain. RT–PCR analyses of Tau exon 10 inclusion in the temporal cortex of 4 con
10, from 3 independent experiments. Tau exon 10 inclusion is signiﬁcantly reduced in DM1a a2 (Fig. 2, histogram). To estimate Tau exon 10-inclusion, primers in
exons 9 and 11 were used. The splicing of exon 10wasmeasured in the
hippocampus, temporal, parietal entorhinal, and frontal cortices of a
control, DM1a, and DM1e patients (Fig. S2). On average, the percentage
of Tau exon 10 inclusion in the control brain regions was of 47%±2%,
consistent with the fact that half of the 6 Tau isoforms contain exon 10.
Onaverage, in bothDM1a andDM1e, a reduced inclusionof exon10was
observedwhen compared to the control (DM1a, 23%±4%;DM1e, 31%±
2%). Apart from the parietal cortex of DM1a, the reduced inclusion of
exon 10 was similar between brain regions analyzed. We further
compared the splicing pattern of exon 10 in the temporal cortex
between 4 controls and 5 DM1 brains at our disposal. In the temporal
cortex of the 4 controls, the percentage of Tau exon 10-inclusion was of
46.5%±1.5% and homogeneous. In DM1a, there was a signiﬁcant
reduction of Tau exon 10-inclusion to 37%±3% (p=0.0013) (Fig. 2B).
Tau exon10-inclusionwas also reduced in thebrain of DM1e (38%±2%;
p=0.002). In contrast, this reduction was not observed in DM1b, c, and
d. Thus, the modiﬁed splicing of Tau exon 2 is a robust and common
phenotype in all DM1 brains analyzed so far, and it is also homogenous
among brain areas. In contrast, the reduced inclusion of exon 10 is less
pronounced and not constant in DM1 patients. One of the possible
factors known to inﬂuence Tau exon 10 splicing isMAPT gene haplotype
(H1 or H2), which has been suggested to modify the level of exon 10-
inclusion [34]. Thus, we genotyped all patients included in the present
study. DM1 patients were all H1/H1 (data not shown), excluding the
possibility that variation of Tau exon 10 splicing could have been related
to polymorphisms ofMAPT gene haplotype.1a and DM1e. Left panel (DM1e not shown): Tau exon 2/3 forward and reverse primers
but not3 (2+3−), or lackingbothexons (2−3−). PCRwasperformedusing samples from
l brain regions of a control individual and patient DM1a. 18S RNA was used as the internal
2 in the brain of DM1a and DM1e. Themean and standard deviationwere calculated from
ntrols (in black) and patients DM1a and DM1e (in white). ⁎⁎⁎pb0.0001. B) Tau exon 10
trols and 5 DM1 patients. Histograms indicate the percentage of transcripts including exon
nd DM1e but not in DM1b, c, or d. ⁎⁎pb0.01.
Fig. 3. Effect of long CTG repeats and MBNL1 loss-of-function on Tau splicing. A) Overexpression of long CUG repeats in HeLa cells mimics the Tau exon 10-exclusion observed in the
brain of DM1a and DM1e. The 3′ UTR of the human DMPK (1 μg) containing 5 (CTG5), 200 (CTG200), or 960 CTG (DT960), subcloned in a pcDNA3.1 plasmid, were transiently
transfected in HeLa cells (left panel). HeLa were also transfected with empty pcDNA 3.1 plasmid DT960 and CTG960 vector, which lacks DMPK exons 11 to 14 and only contains the
CTG repeats (right panel). Total RNA was isolated 48 h post-transfection. Primers Tau exon 10 forward and reverse allowed the simultaneous ampliﬁcation of Tau isoforms with or
without exon 10. 18S RNA was used as the internal loading standard. After polyacrylamide gel electrophoresis, bands were quantiﬁed and results are expressed as the percentage of
Tau exon 10 inclusion. Histogram represents the mean±SEM of four individual experiments. *pb0.05; ns indicates non-signiﬁcant; Mann–Whitney U test. B) Loss of MBNL1
expression reduces Tau exon 2-inclusion. The histogram is representative of 3 individual experiments and values are expressed as mean±SEM. **pb0.01. C) Tau exon 10 splicing is
insensitive to MBNL1 loss of expression using siRNA. The PCR gel represents the results obtained with two RNA duplexes targeting human MBNL1, siMBNL1a (lanes 6–8) and
siMBNL1b (lanes 9–11), and one scrambled duplex (siMBNL1 Scr, lanes 3–5) that were used for transfection into HeLa cells. Lanes 1–2: control (Ctrl), transfection agent alone. ns
indicates non-signiﬁcant; Mann–Whitney U test. Means and standard deviations were calculated for 3 individual experiments. D) Evaluation of incremental concentrations
(siMBNL1 50, 100, and 200 nM) of siMBNL1a upon Tau exon 10 splicing. The histogram represents the average±SEM of percentage of Tau exon 10-inclusion obtained from 3
independent experiments (ns indicates non-signiﬁcant).
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The effect of DMPK long CTG repeats on Tau exon 10 splicing was
next investigated (Fig. 3A). Tau exon 10 splicing is developmentallyregulated—the switch between exclusion and inclusion of exon 10 is
postnatal. Here, we used HeLa cells or T98 glioblastoma cells to
analyze the trans-dominant effect of long CUG repeats because,
opposite to neuroblastoma cell-line SY5Y, exon 10 is alternatively
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Fig. 4. CELF2 and CELF4, but not CELF1, regulate Tau exon 2 and Tau exon 10 splicing.
A) CELF1 expression has no effect on Tau exon 2 and Tau exon 10 splicing (means±SEM
of 4 independent experiments performed in triplicate). Histograms indicate the
percentage of Tau exon 2 and exon 10-inclusion in controls (Ctrl) and in HeLa cells
ectopically expressing CELF1. ns indicates non-signiﬁcant; Mann–Whitney U test.
B) Overexpression of CELF2 reduces the inclusion of Tau exons 2 and 10 (means±SEM
of 5 independent experiments performed in triplicate). ⁎⁎pb0.001, ⁎⁎⁎pb0.0001,
Mann–Whitney U test. C) Overexpression of CELF4 decreases Tau exon 2-inclusion and
increases Tau exon 10-inclusion (means±SEM of 4 independent experiments
performed in triplicate). ⁎⁎pb0.001, Mann–Whitney U test. The control experiments
correspond to the transfection of the pcDNA 3.1 vector.
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control conditions, exon 10 was included in 33%±0.5% and 36%±2%
of HeLa and T98 Tau transcripts, respectively (Fig. 3A and S3A). We
transfected HeLa and T98 with CTG5, CTG200, and DT960 constructs, all
under the same CMV promoter. The splicing of exon 10 was not
signiﬁcantly modiﬁed by CTG5 or CTG200 whereas it was moderately
but signiﬁcantly reduced to 29.5%±0.5% (pb0.05) by DT960 in both
HeLa and T98 cells (Fig. 3A and S3A). The splicing of exon 10 was
similarly modiﬁed by CTG960 lacking the preceding DMPK exons 11 to
14, which are present in DT960 construct (Fig. 3A and S3B), or
remained unchangedwith theDMPK 3′UTR lacking themutated allele
(data not shown). Modiﬁcation of Tau exon 10 splicing was not
related to the presence or absence of DMPK exons. Moreover, despite
the differences observed among patients, Tau exon 10 splicing shares
the same sensitivity towards long CUG repeats as other cerebral
transcripts.
2.5. Differential effect of MBNL1 and CELF proteins on Tau splicing
The loss-of-function of MBNL1 is instrumental in the pathophys-
iology of DM1 due to its sequestration into ribonucleoprotein
aggregates. As shown in Fig. 3B, the inactivation of MBNL1 expression
with two siRNA duplexes—siMBNL1a and siMBNL1b—signiﬁcantly
reduced the inclusion of Tau exon 2, attesting the efﬁcacy of siRNA
duplexes. Incremental doses from 50 to 200 nM of siMBNL1a duplex
were also evaluated and the repression of Tau exon 2-inclusion was
already observed at 50 nM (Fig. S3C). However, MBNL1 siRNA did not
signiﬁcantly modify the inclusion of Tau exon 10, regardless of the
duplex used (Fig. 3C, histogram and PCR) or the concentration used
(Fig. 3D and S3D).
The CELF family also plays a role in DM1 pathophysiology. Moreover,
we previously demonstrated the repressive role of CELF2 and CELF4
proteins in Tauexon2-inclusion [33].Moreover, CELF3 andCELF4 splicing
factors promote the inclusion of Tau exon 10 [18,35]. However, we do not
knowwhether Tau exon10 splicing is sensitive to CELF1 or CELF2 splicing
factors. We therefore analyzed the effect of CELF1, CELF2, or CELF4
overexpression on the splicing of Tau exons 2 and 10. For siRNA
experiments, two independent CELF1 siRNAwere tested and incremental
concentrationswere evaluated (Fig. S4A andB). CELF1mRNAandprotein
expressionweremore strongly reducedby siCELFa thanwith siCELFb(Fig.
S4A). The formerwas therefore selected for the subsequent experiments.
Neither CELF1 overexpression (Fig. 4A) nor silencing (Fig. S4C andD) had
an effect upon the splicing of Tau exons 2 and 10. In contrast, CELF2 and
CELF4 signiﬁcantly reducedTauexon2-inclusionby17%(p=0.0001) and
by 12% (p=0.0012), respectively (Fig. 4B and C). Interestingly, we
observed opposing effects of CELF2 and CELF4 on Tau exon 10 splicing.
The overexpression of CELF2 signiﬁcantly reduced exon 10-inclusion
from 37.5% to 31.7% (p=0.0031) (Fig. 4B), whereas CELF4 promoted the
inclusion of exon 10 by 8% (p=0.044; Fig. 4C). CELF4 was described
previously as an enhancer of Tau exon 10-inclusion [36]. To exclude a
potential artifactual effect due to the efﬁcacy of the vectors or cell-type
used, we co-transfected CELF1, CELF2, or CELF4 with the hcTNT exon 5-
minigene or a dominant-negative CELF vector (DN-CELF) and reproduced
the experiments using both HeLa and T98 cells (Fig. S5B and C). All CELF
proteins were expressed as assessed by Western blotting using a V5-
epitopeantibody forCELF1, 2, and4 factors orXpress-epitopeantibody for
the DN-CELF factor (Fig. S5A). All CELF factors except the DN-CELF
promoted the inclusionof exon5, aspreviouslydemonstrated [37] inboth
HeLa and T98 cells (Fig. S5B and C). Finally, Tau exon-10 inclusion was
promoted by CELF4 and repressed by CELF2 but neither by CELF1 norDN-
CELF in both T98 and HeLa cells (Fig. S6).
As several CELF familymembers appear tobemodulators of Tauexon
10 splicing, we ﬁnally analyzed the expression of CELF1, CELF2, and
CELF4 in brain tissues of DM1 patients as compared to controls (Fig. 5).
CELF1, CELF2, and CELF4 were more strongly detected in the temporal,
parietal, and frontal cortices of DM1a and DM1e than in samples fromthe control or patients DM1b, c, or d (Fig. 5A, B, and C). In sharp contrast,
in the three latter cases, while CELF4 levels were similar to those
observed in the control, CELF2 and CELF1 levels were diminished.3. Discussion
Our data together suggest that the reduced inclusion of Tau exon
10 is not a ubiquitous splicing event in DM1 brains and is probably not
related to a loss of MBNL1 or gain of CELF1 functions but rather to a
gain of CELF2 function, shown herein to repress Tau exon 10 inclusion.
Moreover, the loss of MBNL1 function and gain of CELF function, as far
as the brain is concerned, can occur simultaneously or individually
and may explain the discrepancies observed in splicing events such as
Tau exon 10 splicing.
Fig. 5. CELF protein expression in brain tissues. Western blots revealing an overexpression of CELF1 (A) and CELF2 (B) proteins in DM1a and DM1e, using brain tissue lysates from the
temporal (T), parietal (P), and frontal cortices (F) of a control individual and patients DM1a, b, c, d, and e. Membranes were stripped and probed with a GAPDH antibody for
standardization.
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moderate symptoms
In this study, we described the topographical distribution of NFTs in
two patients. These patients presentedwith a classic adult formof DM1.
DM1awas diagnosed at 46 years and displayedmuscular abnormalities
and early-onset bilateral cataract. He had no cardiac or endocrine
disorders nor any cognitive impairment from a clinical point of view.
The only neurological symptom reported was diurnal somnolence. The
anamnesiswasmarked by frequent gastrointestinal disorders leading to
a grade 3 adenocarcinoma of the colon, which was the cause of death.
DM1ewas diagnosed at the age of 45 years and had a round, myopathic
face; myotonia of both hands; type II diabetes; hypercholesterolemia;
and suffered from obesity. Although we do not know the cognitivestatus of these patients, the topographical distribution of NFTs was very
similar to that of DM1 patients already characterized [15]. In our DM1
cohort, we show that Tau pathology is observed early in adulthood and
that the hippocampus and temporal cortex, aswell as the amygdala and
insula, are themost vulnerable regions affected inDM1. Importantly, the
amygdala is the brain region controlling fear and facial emotion
recognition. In DM1, the latter cognitive function is altered [5].
Moreover, brain imaging also points to the temporo-insular region as
a vulnerable brain area [11,38].
3.2. Analysis of splicing modiﬁcations in DM1 brains
Although the presence of NFTs is restricted to the hippocampus
and temporal amygdala in our study, Tau splicing is altered in all
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populations, as observed in other Tauopathies [17,39,40]. Our results
show that all DM1 patients, in all brain regions and regardless of the
size of the expansion, present a reduction in the inclusion of Tau exon
2. In addition, wewere able to conﬁrm a similar ubiquitous increase in
the expression of the APP fetal splice variant lacking exons 7 and 8, an
increase in the inclusion of NMDAR1 exon 5 [20], and an increase in
the expression of the longest MBNL1 isoform, MBNL143 [19] (not
shown). In contrast to these splicing mechanisms, we found that Tau
exon 10 skipping is not a consistent feature of DM1. Indeed, only 2
among 6 patients presented an abnormal inclusion of Tau exon 10.
The 10 DM1 patients previously investigated by Jiang et al. also
displayed Tau exon 10 mis-splicing [20]. MAPT polymorphism has
been reported to inﬂuence Tau expression and splicing. In fact, H1
carriers have an increased susceptibility to neurodegeneration, and
the H1 chromosome results in higher levels of exon 10+MAPTmRNA
than H2 [34]. We systematically genotype all patients in our cohort,
and all our cases—DM1 and controls—were H1/H1. Moreover, the
MAPT gene between exon 9 and exon 10 was sequenced in DM1a and
DM1b to exclude any unknown polymorphism. Thus, even if NFTs
were observed, theMAPT haplotype could not explain the differential
inclusion of exon 10 in DM1 patients. However, exon 10 splicing is
sensitive to the identity of its ﬂanking exons. Indeed, exon 9 promotes
skipping whereas exon 11 is repressive [36,41].
The mechanism underlying the mis-splicing of Tau exon 10 in DM1
remains completely ill-deﬁned. An alternative explanation, that exon 10
mis-splicing is not directly related to CTG expression, can be ruled out.
In vitro experiments using long CUG tracts lead to a modiﬁcation in Tau
exon 10 splicing, as observed in the human brain. Moreover, a reduced
inclusion of Tau exon 10 has also been reported in a mouse model of
DM1 [21]. The CUG expansion sequesters MBNL1, resulting in the mis-
splicing of transcripts regulated by this splicing factor. The loss of
MBNL1 function can be mimicked using speciﬁc siRNAs that target
MBNL1 transcripts. Surprisingly, Tau exon 10 splicing is not signiﬁcantly
modulated by a loss ofMBNL1expression, in contrast to Tau exon 2 [19].
The splicing event that we demonstrate here thus appears to be a
misregulation induced by long CUG repeats but probably independent
of an MBNL1 loss-of-function, as previously suggested for splicing
events regulated by CELF1 but not by MBNL1 [30].
3.3. Analysis of CELF proteins: expression and splicing regulation
The present study reports CELF protein expression in DM1 brains.
We show that CELF1, CELF2, and CELF4 proteins are expressed in the
human brain. Interestingly, an increase in protein levels of CELF1 and
CELF2 was observed in the brains of patients DM1a and DM1e but not
in the 3 other DM1 patients. GAPDH and CELF4 levels were similar in
DM1 and control cases, suggesting that the differences observed were
not due to the post mortem delay or the quality of the tissue. Post-
translational modiﬁcations of splicing factors can modulate their
activity. With regard to Tau exon 10 splicing, phosphorylation of the
splicing factor hTra21 or SR proteins by the kinases CLK2 or GSK3
promotes the skipping of exon 10 [42–44]. The stability and activity of
CELF1 protein is regulated by phosphorylation [30]. Notably, we also
observed an increase in CELF1 protein steady-state levels in DM1a and
DM1e. CELF1 and CELF2 sharemore than 70% sequence homology [45]
and preliminary data using 2D electrophoresis and Western blotting
suggest that CELF2 is also hyperphosphorylated in DM1 brains (data
not shown). Therefore, in addition to protein expression, phosphor-
ylation should also be considered to be amodulator of splicing activity
in DM1 heart, muscle, and brain.
The splicing of several transcripts (NMDAR1 [20]; cTNT [46]; IR [47];
MTMR1 [48]; and ClC-1 [49]) is modulated by CELF1. However, we
found that the overexpression or inactivation of CELF1 does not
modulate the splicing of Tau exons 2 and 10. CELF4 promotes Tau
exon 2 splicing whereas CELF2 represses it [33]. CELF4 has also beenshown to promote Tau exon 10 inclusion [36] but the potential
regulation of Tau exon 10 splicing by CELF2 remains unexplored. In
this paper, we used HeLa and T98 cells, in which the endogenous
expression of CELF4 and CELF2 is lacking [33,50], to show that the
ectopic expression of CELF4 promotes Tau exon 10 inclusion whereas
CELF2 represses it. Thus, whereas these 3 CELF proteins promote hcTNT
exon 5-inclusion, the role of each CELF in Tau splicingwas distinct from,
and sometimes the opposite of, that of the others, evenwith respect to a
single exon, as reported for α-actinin [51] in non-muscle cells.
Therefore, we demonstrate here for the ﬁrst time that CELF1 has no
effect on Tau exons 2 or 10, CELF2 is a repressor of both exons, whereas
CELF4 is a repressor of exon 2 and an activator of exon 10 inclusion.
Togetherwith other data, we demonstrate that two CELF family splicing
factors are strong modulators of Tau splicing [18,33,35]. In addition to
these results obtained in vitro, we observed a potential relationship
betweenCELF2 overexpression inDM1 and themis-splicing of Tau exon
10. Since CELF2 levels in DM1b, DM1c, and DM1d were lower than in
DM1a and DM1e, and since the former patients showed no change in
exon 10,we suggest that Tau exon 10-inclusion is likely related to CELF2
expression or activity in the DM1 brain. It has previously been shown
that high levels of CELF2 protein in the forebrain are associated with a
skipping of the NMDAR1 NI exon and inclusion of the CI exon and that
these splicing patterns are reversed in the hindbrain where CELF2 is
deﬁcient [52]. A competitive effect of CELF2 and CELF4 is therefore
possible. As CELF2 protein is expressed at higher levels than CELF4 in the
brains of DM1a and DM1e, the repressive effect is stronger than the
activator effect. InDM1b, c, and d, the disparity betweenprotein levels is
not as great and may explain why the promoting effect of CELF4 is in
balance with the repressive activity of CELF2.
In conclusion, we show that the altered splicing of Tau exon 10 is
likely related to a gain of CELF2 function and neither to a loss of
MBNL1 nor a gain of CELF1 functions. Our results strengthen the idea
that the CELF proteins are involved in the neuropathology of myotonic
dystrophy type I. Noteworthy, CELF2 polymorphisms in combination
with Apoliprotein E4 allele are associated with the risk of developping
Alzheimer's disease in a recent genome wide association study [60].
Moreover, since neuroﬁbrillary degeneration is a feature common to
DM1 patients, particular attention should be paid to cognitive
dysfunction related to the temporo-insular brain region.
4. Materials and methods
4.1. DM1 patients and human brain tissue samples
DM1a was a patient followed at the Department of Neurology,
Donostia Hospital, San Sebastian, Spain. This patient was amale from the
Basque Country in the north of Spain and diagnosed with myotonic
dystrophy at the age of 46, with a smear expansion of 333 to 833 CTG
triplets as established from blood cells. The initial symptom reportedwas
a cataract operated at the age of 32. In association with typical DM1
symptoms, the patient presented diurnal somnolence, trigeminal
neuralgia, and hepatic steatosis. In the last ﬁve years, he presented severe
proximal weakness that brought him to a wheelchair-bound state. The
patient died at 60 years fromadisseminated colonneoplasia. DM1ewas a
woman diagnosed at the age of 46 years old. She presented a myopathic
face, suffered from myotonia of both hands, and had type II diabetes,
hypercholesterolemia, obesity, and severe restrictive ventilation. Cogni-
tive status was not assessed in either case. Brain tissue samples were
obtained at autopsy in accordance with the protocol of the local ethics
committee. Theother 3DM1patients, DM1b,DM1c andDM1d,havebeen
previously described (reference 15 and correspond to case 3, case 1, and
case 2, respectively; [19]). These 3 patients were 64, 61, and 53 years old,
respectively, at the time of death. Three control individualswere included
in the study. Post-mortem delays for tissue sampling were below 48 h.
One cerebral hemisphere was frozen and stored at−80 °C and the other
was formalin ﬁxed for histological and immunohistochemical studies. Six
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parietal cortices, and the hippocampus—were dissected for analysis. Due
to the limited amount of tissue for certain brain regions, such as the
hippocampus and entorhinal cortex, biochemical analyses were per-
formed using the temporal, frontal, and parietal cortices. For genetic
analysis, all brain regions were included.
4.2. Immunohistochemical analysis
Immunostaining was performed with parafﬁn-embedded sections.
Sections (5 μm-thick) were deparafﬁnized with xylene and rehydrated
through decreasing concentrations of ethanol. Endogenous peroxidase
activitywasquenchedwithH2O2 andnon-speciﬁc stainingblockedwith
horse serum using the Vectastain ABC Universal Kit according to the
manufacturer's protocol (Vector Laboratories). Brain tissue slices were
incubated overnight with the following primary antibodies: AT8, AD2,
AT100, S199P, Exon 2, Exon 10, and TauCter. AT8, AT100, Exon 2 (Clone
DC 39 1N; Sigma), and Exon 10 (DC 4R; Sigma) are mouse monoclonal
antibodies. TauCter and S199P antisera were developed in rabbits
against synthetic peptides [15]. AT8 and AT100 label phosphorylated
Tau epitopes: AT8 speciﬁcally detects phospho-serine 202 and
phospho-threonine 205, while AT100 recognizes the pathological
phospho-Tau epitopes at serine 212 and threonine 214. Antibodies
were diluted 1/100 to 1/1000 in PBS.
4.3. Determination of CTG repeats size and Tau haplotype
Genomic DNAwas prepared from brain tissue by phenol–chloroform
extraction. The genetic diagnosis of DM1 was conﬁrmed by PCR
ampliﬁcation of the CTG region according to the protocol of Cheng [53],
using an Expand Long Template PCR System™ (Roche Diagnostics GmbH,
Mannheim, Germany). Each 50 μl reaction consisted of 1× Expand Long
PCR Buffer; 0.7 mM each of dATP, dCTP, and dTTP; 0.06 mM dGTP;
0.24 mM 7-deaza dGTP; 1 μM of primers DMK1 (5′-CACAGGCT-
GAAGTGGCAGTTCCA-3′) and DMK2 (5′-TGTCGGGGTCTCAGTGCATCCA-
3′); 3.5 U of Taq DNA polymerase; 1.75 mM MgCl2; and 0.01 to 5 ng of
total genomic DNA. Ampliﬁcations were performed in a PTC200
thermocycler (MJ Research, Prolabo, France). Following denaturation
for 5 min at 95 °C, 35 cycles of ampliﬁcation were performed:
denaturation at 95 °C for 1 min, annealing at 62 °C for 30 s, and extension
at 68 °C for 10 min. PCR products were resolved on 1% agarose gels.
Southern blot transfer and probe-mediated detection was carried out as
follows: agarose gels were denatured in 0.4 M NaOH and 0.6 MNaCl and
rinsed twice in 2× SSC before being transferred to Hybond N+ nylon
membranes. Blots were pre-hybridized in DIG Easy Hyb solution (Roche)
for 30 min at 59 °C. Hybridization was performed in a fresh solution
containing 100 pmol 3′-DIG-(CTG)10 (DIG Oligonucleotide Terminal 3′
Labeling Kit; Roche) for 2 h at 59 °C, followed by 2washes in 2× SSC, 0.1%
SDSat roomtemperature for5 min, and2washes in0.5×SSC, 0.1%SDS for
15 min at 59 °C. Probe binding was detected using a DIG LuminescenceTable 1
Clinical, genetic, and neuropathologic characteristics of four DM1 patients.
Case Age at death Phenotype class Intellectual and cog
AD – Alzheimer's disease Demented
DM1a 60 Adult form Not evaluated
DM1b 64 Adult form Cognitive impairme
DM1c 61 Adult form Normal
DM1d 53 Congenital form Mental retardation,
cognitive impairme
DM1e 61 Adult form Not evaluated
NFT indicates neuroﬁbrillary tangles.Detection Kit (Roche) according to the manufacturer's instructions
(Amersham-Pharmacia Biotech, Orsay, France). Film exposure times
ranged from 2 to 5 min. DNA molecular weight standards were loaded
onto each agarose gel (DNA Marker IV; Boehringer Mannheim GmbH,
Germany). Tau H1/H2 genotyping was performed with primers ﬂanking
the 236 bp insertion/deletion polymorphism in intron 9. The forward (5′-
GGAAGACGTTCTCACTGATCTG-3′) and reverse (5′-AGGAGTCTGGCTT-
CAGTCTCTC-3′) primers used have been previously described [54].
4.4. Semi-quantitative analysis
Total RNA was isolated from brain tissue using RNAgents (Promega,
Madison, USA) according to the manufacturer's instructions. Total RNA
was isolated from cells using the Nucleospin® RNA II Kit (Macherey
Nagel, Düren, Germany). RNA concentration was determined by
absorption at 260 nm with NanoDrop ND 1000 Technology (Labtech,
France). RT–PCRwasperformed in triplicatewith 1 μg of total RNAusing
random hexamers (5 μM/l) and M-MLV reverse transcriptase (Invitro-
gen, CA, USA) according to standard protocols. No DNA ampliﬁcation
was observed in RT controls. PCR was carried out in a ﬁnal volume of
25 μl, with 10 or 15 pMof eachprimer (primer sequences are detailed in
Supplementary Table 1), 1.5 mM MgCl2, and 1 U of Taq polymerase
(Invitrogen), under the following conditions: 5 min at 94 °C, 22 to 30
cycles of a 1 min denaturation step at 94 °C, annealing for 2 min at the
temperature indicated in Table 1, 2 min of extension, and 7 min of ﬁnal
extension at 72 °C. 18S was used as an internal control. Reaction
products were resolved by electrophoresis using a 4%, 5%, or 8%
polyacrylamide gel, and bands were stained with SYBR Gold (Invitro-
gen). The intensity of SYBR Gold luminescence was measured using a
FluoroImager scanner (Claravision, France). The mRNA signals were
normalized to that of 18S mRNA.
4.5. Protein extraction and Western blot analysis
DM1 and control brains were homogenized with a Dounce
homogenizer in RIPA buffer (Invitrogen, CA, USA) with the addition
of 1 mM Na3VO4, 125 nM okadaic acid, and protease inhibitors. The
resulting homogenates were sonicated and spun at 13,000g for 20 min
at 4 °C. The supernatants were transferred and the concentration of
proteins measured. The pellets were sonicated again, warmed, and
centrifuged. The supernatants were diluted with 2× Laemmli Lysis
Buffer (LDS Buffer; Invitrogen). The protein extracts (5 μg each) were
used for SDS–PAGE (4%–12%; NuPAGE® Bis–Tris Gels; Invitrogen, CA,
USA) and transferred onto Hybond nitrocellulose membranes (G&E
Healthcare) using the XCell™ II Blot Module (Invitrogen). Proteins
were reversibly stained with Ponceau red in order to control for the
amount of protein loaded. After blocking with 5% skimmed milk in
TBS-T (20 mM Tris–HCl pH 8.0, 150 mM NaCl, and 0.1% Tween-20),
membranes were incubated overnight at 4 °C with the following
antibodies in the same buffer: anti-CELF1 (Clone 3B1, mousenitive status Neuropathology Cortical area and size range of the
longest (CTG)n expansion
NFT –
NFT Entorhinal
150–1180
nt NFT Temporal
150–3300
NFT Temporal
150–2800
progressive
nt
NFT Temporal
1000–2400
NFT Temporal amygdala
140–1820
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anti-CELF4 (anti-Brunol4, mouse polyclonal, 1:500; Abcam, Cam-
bridge, UK), anti-CELF2 (anti-CUGBP2, mouse monoclonal, 1:1000;
Sigma-Aldrich, Saint Louis, MO, USA), and anti-GAPDH as an internal
control (anti-FL-335, 1:10,000; Tebu-Bio, Le Perray en Yvelines,
France). To label Tau isoforms, we used antibodies speciﬁc to exon
2+ (Clone DC 39 1N, 1:1000; Sigma), exon 10+ (DC 4R; Sigma), and
Tau exon 10− (anti-Tau 3R-repeat isoform RD3, clone 8E6/C11,
1:1000; Millipore). Membranes were subsequently incubated with a
peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich; 1:50,000
in the same buffer) or with peroxidase-conjugated goat anti-rabbit
IgG (Sigma-Aldrich; 1:4000 in the same buffer), and labeling was
revealed using ECL™ and Hyperﬁlms (G&E, Amersham) according to
the manufacturer's instructions. Western blots were carried out at
least twice.4.6. Cell culture and transfection
HeLa cells or T98 glioblastoma cells were grown in monolayer
cultures in 6-well plates in Dulbecco's Modiﬁed Essential Medium
(DMEM) (GIBCO; Invitrogen, CA, USA) supplemented with 10% fetal
calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 4 mmol/l
glutamine, at 37 °C in a humidiﬁed 5% CO2 incubator. Cells grown
to ~50% conﬂuence were transiently transfected with 1 or 3 μg of
plasmid DNA, using FuGENE HD transfection reagent (Roche Di-
agnostics, IN, USA). Total RNA was analyzed 48 h post-transfection,
with 18S RNA as an internal loading standard.
CELF1, CELF4, andCELF2 cDNA inTOPOvectorswere sub-clonedusing
the Gateway System (Invitrogen, France) and inserted into pcDNA3.1/
nV5-DEST™ (Invitrogen, France). A V5-epitope was fused to the N-
terminal region of CELF factors and their expression was analyzed using
both CELF antibodies and a V5-speciﬁc antibody (Invitrogen; 1:10,000
dilution). The dominant-negative CELF factor in pcDNA 3.1-His vector
(Invitrogen, France) was kindly provided by Thomas Cooper (Baylor
College of Medicine, Houston, TX, USA) and corresponds to a CELF4
deletion that has dominant negative activity on itself and other CELF
proteins [37]. The protein expression was veriﬁed with an Xpress™-
speciﬁc antibody (Invitrogen) of which epitope is localized at the amino-
terminus of the protein. The pcDNA 3.1 empty vector was used as a
control. Plasmids containing the 3′ UTR of DMPK with 5 or 200 CTG
repeats were derived from previously described constructs under a
rodent ROSA promoter controlling GFP fused to the 3′UTR of DMPK [55].
The constructs were sub-cloned into the pcDNA 3.1 vector (Invitrogen,
France) under the control of the CMV promoter. The plasmid containing
the3′UTRofDMPKwith960 interruptedCTGswasaminigenevector also
under the control of the CMV promoter named DT960. It contained the
last 5 exons of the DMPK gene followed by the full length DMPK 3′ UTR,
with 960 CTG repeats interrupted at every 20th repeat by a CTCGAmotif
[56], named herein CTG960. The conservation of the number of CUG
repeats was veriﬁed by a long PCR assay. The RTB300-minigene
containing exon5of human cTNT (hcTNT) has beenpreviously described
[57].
For silencing experiments, siRNAswere synthesized by Eurogentec
(Belgium). The sense strand sequences of the siRNAs designed to
target MBNL1 mRNA transcripts were siMBNL1a 5′-CGCAGUUGGA-
GAUAAAUGG-3′ and siMBNL1b 5′-CAGACAGACUUGAGGUAUG-3′
[58]. To target CELF1 mRNA transcripts, the sense strand sequences
of the siRNAs were siCELF1a 5′-GUUACGACAAUCCUGUUUCdTdT-3′
(described by Paul et al. [59]) and siCELF1b 5′-CACCCGUAAAGCUG-
CAUUdTdT-3′. Scrambled siRNAs and siRNA against β-actin were also
designed as controls. The siRNAs were transfected using Oligofecta-
mine Reagent (Invitrogen) according to the manufacturer's instruc-
tions. Increasing concentrations were used (10, 50, 100, and 200 nM)
to determine the dose–response curve; otherwise, siRNA concentra-
tion used was 100 nM.4.7. Statistical analysis
Statistical analyses were performed using the non-parametric Mann–
Whitney test or one-way ANOVA, using Prism Software (GraphPad
Software Inc., San Diego, CA, USA).
Supplementarymaterials related to this article can be found online
at doi: 10.1016/j.bbadis.2011.03.010.
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